Woodward D F, Spada C S, Hawley S B, Williams L S, Protzman C E, Nieves A L
Department of Biological Sciences, Allergan, Inc., Irvine, CA 92713-9534.
Eur J Pharmacol. 1993 Jan 19;230(3):327-33. doi: 10.1016/0014-2999(93)90569-4.
Prostaglandin D2 (PGD2) and the selective DP receptor agonist BW 245C have been previously shown to lower intraocular pressure in rabbits, while PGD2, but not BW 245C, caused plasma extravasation, eosinophil infiltration, and goblet cell depletion. In these present studies definition of the ocular pharmacology of prostaglandin D2 (PGD2) has been extended by using a further selective DP receptor agonist SQ 27986 and a potent and selective DP receptor antagonist BW A868C. In cats and rabbits SQ 27986 caused ocular hypotension. The ocular hypotensive effect of PGD2 in rabbits was blocked by pretreatment with the DP receptor antagonist BW A868C, whereas the activities of PGE2 and PGF2 alpha remained unaltered. The singular involvement of the DP receptor in changes in rabbit intraocular pressure evoked by PGD2 was thereby verified by using the antagonist BW A868C. In terms of effects on the ocular surface, SQ 27986 caused no increase in conjunctival microvascular permeability, no eosinophil infiltration, and no depletion of the goblet cell population. These findings reinforce the concept that selective DP receptor agonists may be useful for lowering intraocular pressure without causing ocular surface pathology. PGD2 induced increases in conjunctival microvascular permeability were inhibited by BW A868C, despite the fact that DP receptor agonists failed to evoke a plasma exudation response. This finding was unexpected and suggests a possible subdivision of the DP receptor designation.
前列腺素D2(PGD2)和选择性DP受体激动剂BW 245C先前已被证明可降低兔眼压,而PGD2(而非BW 245C)会导致血浆外渗、嗜酸性粒细胞浸润和杯状细胞减少。在这些当前研究中,通过使用另一种选择性DP受体激动剂SQ 27986以及一种强效且选择性的DP受体拮抗剂BW A868C,对前列腺素D2(PGD2)的眼部药理学定义进行了扩展。在猫和兔中,SQ 27986引起眼压降低。用DP受体拮抗剂BW A868C预处理可阻断PGD2对兔的眼压降低作用,而前列腺素E2和前列腺素F2α的活性保持不变。由此通过使用拮抗剂BW A868C证实了DP受体在PGD2引起的兔眼压变化中单独起作用。就对眼表的影响而言,SQ 27986未引起结膜微血管通透性增加、嗜酸性粒细胞浸润和杯状细胞数量减少。这些发现强化了这样一种观念,即选择性DP受体激动剂可能有助于降低眼压而不引起眼表病变。尽管DP受体激动剂未能引发血浆渗出反应,但BW A868C抑制了PGD2诱导的结膜微血管通透性增加。这一发现出乎意料,并提示DP受体命名可能存在细分。